Platelet-rich Plasma Injection for Ulnar Neuropathy at Elbow

Yung-Tsan Wu30 enrolled

Overview

Ulnar neuropathy at elbow (UNE) is the second common peripheral entrapment neuropathy after carpal tunnel syndrome (CTS). Although many conservative managements of UNE were found, their effectiveness were often unsatisfied without existed guideline. Recently, the perineural injection of 5% dextrose wate (D5W) is a novel management for CTS but its effect for UNE is not obviously as CTS. Hence, it is very important to find another novel injectate for UNE.

The platelet-rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders and recent reports showed being beneficial for peripheral neuropathy in animal studies. Our previous research shown single injection with PRP was superior to D5W for CTS. However there is no study investigating the effect of PRP for UNE now. Hence, the purpose of this study was to assess the effect of perineural PRP injection for UNE.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Ulnar Neuropathy at Elbow

Interventions

platelet-rich plasmaDRUG

Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve

5% dextroseDRUG

Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age between 20-80 year-old. 2. Diagnosis as ulnar neuropathy at elbow at least one month Exclusion Criteria: 1. Cancer 2. Coagulopathy 3. Pregnancy 3\. Any active infection status 4. Polyneuropathy of upper extremity 5. Brachial plexopathy 6. Thrombocytopenia Previously undergone wrist surgery or steroid injection for ulnar neuropathy

Locations (1)

Yung-Tsan Wu

Taipei, Neihu District, Taiwan

Outcomes

Primary Outcomes

Visual analog scale (VAS)

Digital pain severity or paresthesia/dysthesia was evaluated using VAS. Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain.

Time frame: Change from baseline at 6 month after injection

Secondary Outcomes

Disabilities of the Arm, Shoulder and Hand (DASH)

Taiwan Disabilities of the Arm, Shoulder and Hand (DASH) contains 11-item disability/symptom scale and each item has five levels of response scoring from 1 to 5. The higher score means more disability or severer symptoms.

Time frame: Change from baseline at 6 month after injection

Electrophysiological study

Nerve motor conduction velocity of the ulnar nerve before treatment and multiple time frame after treatment.

Time frame: Change from baseline at 6 month after injection

Cross-sectional area of ulnar nerve

Using the musculoskeletal sonogram to measure the cross-sectional area of the ulnar nerve before treatment and multiple time frame after treatment.

Time frame: Change from baseline at 6 month after injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.